Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Autolus Therapeutics plc
< Previous
1
2
Next >
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
August 27, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
May 31, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 17, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
May 13, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
April 24, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
April 02, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
February 29, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Announces Pricing of Underwritten Offering
February 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
November 15, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit